LinkedIn

Product pipeline

Our investigational medicines offer simple new ways for patients and caregivers to use proven and trusted molecules.

Invest in the future of 
simplified medicine delivery

Our pipeline is built around two core technologies. Our PharmFilm® technology provides precise, reliable dosing through non-invasive buccal, sublingual, and lingual film options. Complementing this is our AdrenaVerse™ platform, a proprietary prodrug technology enabling localized, sustained delivery of epinephrine across mucosal and dermal surfaces—a new frontier in epinephrine-based therapies.
Learn more about our core technologies

Complex molecule programs

ANAPHYLAM™
(dibutepinephrine) sublingual film
Potential Indication
Anaphylaxis
Pre-Clinical Phase 1 Phase 2 Phase 3
An oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.
Learn more
AQST-108
(epinephrine) topical gel
Potential Indication
(multiple indications)
Pre-Clinical Phase 1 Phase 2 Phase 3
An oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.

Complex molecule programs

LIBERVANT®
(diazepam) buccal film
Potential Indication
Acute repetitive seizures / cluster seizures
Pre-Clinical Phase 1 Phase 2 Phase 3
An oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.

Looking for clinical trial data?

View the latest posters, presentations, and data with our clinical trial portal.
Visit the portal